Hey Spidey thanks for the reply. Busy is good I hope, as I am as well. Thankfully that will allow me to buy more options as my March ones seem to be coming up faster than ever. Points well taken on all questions.
While zome might think these are invalid questions, I do not. I have always been a fan of the technology, just not management.
Hence the reason for asking about the validity of being called a phase 3 company. The data does look good on all counts, just wasn't sure about the significance of it with such small human numbers. Some good numbers regarding our IC results will put any doubt to ease.
I don't share your optimism on Zami. While yes running a company has similar traits, this complex field they are in is a little different. Connections in the upper levels of management in other big pharma companies would go a long way imo. Just the very name of his "consulting" company says it all. Rose High Tech Ltd.
Having experience would also maybe prevented the missing of targets year after year, and sometimes by years, knowing the complexities and difficulties that can arise in this field.
As for Yaki, see no point in paying him CEO type salary and bonuses. Again, the 2 of them go back a ways, and seems like a complete waste of money to me. Just 2 buddies helping each other out IMO.
And thank you for clarifying the belief that some have that CLI could be approved in 2 weeks to 90 days. Some beliebers out there may have actually believed this. From what I have read, fast track means more frequent meetings with FDA and ability to fill portions of BLA before trial is done, allowing for quicker time frame once trial is over.
Hoping we hear some of these interim results on HCT soon. The study started Feb 8th. All the primary outcome measures have a time frame of a year. So I don't know how they expect to get interim results unless they can before the year has elapsed. Could just be management's projections are exaggerated like usual.
But the estimated completion date is expected to be May 2019. Would have to think they expect all 30 to be enrolled within 5 months. Will be keeping an eye to see if any of these things are changed when they update CT site. It will be a good gauge as well to see how quickly the CLI is progressing as well imo. Even with the "new" person at Pluristem in charge that didn't "drop the ball" like they did in the IC trial like one person here says.
Your previous post on my delay of pivotal ARS trial has given me new hope that maybe this new Bill will get some sort of stock piling contract before approval. Always thoughtthat if they wanted it, they would have gotten this trial started. Your explanation seems reasonable enough for the delay. But you would still think they could announce funding for this trial, in advance of it being ready to go. Then make sure the design of this trial is correct in every way. But like always, we will just have to speculate with any info we find. And of course wait wait wait. The one thing management does best.
Again thank you for your response. A little transparency from management would go a long way. But they've been at this a long time, and don't think that will change ever. They like to keep things under wraps and only the lucky raise participants would get info that us Joe Shmo shareholders could only dream of.
AI
